

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/
Form SC 13D/A
March 08, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

ARRHYTHMIA RESEARCH TECHNOLOGY, INC.

(Name of Issuer)

Common Stock, Par Value \$.01

(Title of Class of Securities)

042698308

(CUSIP Number)

Dr. Julius Tabin
Fitch, Even Tabin & Flannery
120 South LaSalle Street, Suite 1600
Chicago, Illinois 60603
(312) 372-7842

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 10, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box .

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all

other provisions of the Act (however, see the Notes).

CUSIP NO. 042698308

SCHEDULE 13D

PAGE 2 OF 3 PAGES

1. Name of Reporting Persons
 I.R.S. Identification Nos. of above persons (entities only)
 Julius Tabin

2. Check the Appropriate Box if a Member of a Group (See Instructions)
 (a)
 (b)

3. SEC Use Only

4. Source of Funds (See Instructions)
 PF

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization
 U.S.

Number of
 Shares
 Beneficially
 Owned by
 Each
 Reporting
 Person With

7. Sole Voting Power
 118,824 Shares Common Stock, \$.01 Par Value

8. Shared Voting Power

9. Sole Dispositive Power
 118,824 Shares Common Stock, \$.01 Par Value

10. Shared Dispositive Power

11. Aggregate Amount Beneficially Owned by Each Reporting Person
 118,824 Shares Common Stock, \$.01 Par Value

12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares*

13. Percent of Class Represented by Amount in Row (11)
 4.6%

14. Type of Reporting Person (See Instructions)
 IN

*See Instructions before filling out

CUSIP NO. 042698308

SCHEDULE 13D

PAGE 3 OF 3 PAGES

Item 1. Security and Issuer

This statement relates to the \$.01 Par Value Common Stock (Common Stock) of Arrhythmia Research Technology, Inc. (ART), the principal executive offices of which are located at 25 Sawyer Passway, Fitchburg, Massachusetts 01420

Item 2. Identity and Background

- (a) Dr. Julius Tabin
- (b) Dr. Tabin s business address is Fitch, Even Tabin & Flannery, 120 South LaSalle Street, Suite 1600, Chicago, IL 60603
- (c) Dr. Tabin s principal occupation is as a partner in the previous listed law firm.
- (d) Dr. Tabin has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
- (e) Dr. Tabin has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction during the last five years and was not and is not, as a result of any such proceeding, subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Dr. Tabin is a citizen of the United States.

Item 3. Source and Amount of Funds or Other Consideration

This Schedule 13D does not report any acquisition of Common Stock of ART.

Item 4. Purpose of Transaction

This Schedule 13D does not report any acquisition of Common Stock of ART. Dr. Tabin has no present plan or proposal with respect to any action that would relate to or result in: (i) the acquisition by any person of additional securities of ART, or the disposition of securities of ART; (ii) an extraordinary corporate transaction involving ART or its subsidiary; (iii) a sale or transfer of a material amount of assets of ART or its subsidiary; (iv) any change in the present board of directors of ART or management of ART; (v) any material change in the present capitalization or dividend policy of ART; (vi) any material change in ART s business or corporate structure; (vii) any change in ART s certificate of incorporation or bylaws, or other action which may impede the acquisition of control of ART by any person; (viii) causing a class of securities of ART to be delisted from a national securities exchange; (ix) a class of equity securities of ART becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended; or (x) any action similar to any of the foregoing. Dr. Tabin reserves the right to formulate specific plans or proposals with respect to, or to change his intentions regarding, any or all of the foregoing.

Item 5. Interest in Securities of the Issuer

- (a) The aggregate number of shares of Common Stock of ART beneficially owned by Dr. Tabin and the percentage which those shares are of the outstanding Common Stock of ART are as follows:
 Julius Tabin 118,824 shares 4.6%
- (b) Dr. Tabin has the sole power to vote and the sole power to dispose or direct the disposition of all of the shares of Common Stock listed in subpart (a) of this Item.
- (c) The following transactions in Common Stock of ART were completed to reduce ownership to 4.6%:

Date	Amount of Securities	Price / Share	Where and How Effected
12/09/03	5,000	24.00	Sold on Open Market
12/10/03	15,000	23.7667	Sold on Open Market

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

Dr. Tabin does not have any contracts, arrangements, understandings, or relationships (legal or otherwise) with any persons with respect to any securities of ART, including but not limited to transfer or voting of any securities of ART, finders fees; joint ventures; loan or option arrangements; puts or calls; guarantees of profits; divisions of profits or losses; or the giving or withholding of proxies.

After reasonable inquiry and to the best knowledge and belief of each, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated March 1, 2004

/s/ Juilis Tabin
Julius Tabin